FDA approves new diabetes treatment

Oct 17, 2006

The U.S. Food and Drug Administration has approved the use of Januvia tablets as the first in a new class of diabetes drugs.

The new drugs, known as DDP-4 inhibitors, enhance the body's ability to lower elevated blood sugar.

The FDA said it approved Januvia (sitagliptin phosphate) for use by patients with type 2 diabetes, alone or in combination with two other commonly prescribed oral diabetes medications -- metformin or a PPAR (peroxisome proliferator-activated receptor gamma) agonist -- when either of those drugs doesn't provide adequate blood sugar control.

Type 2 diabetes is the most common form of the disease, accounting for about 90 percent to 95 percent of all cases of diabetes. In type 2 diabetes, the body does not produce enough insulin or the cells ignore the insulin.

Januvia was examined in 2,719 patients with type 2 diabetes during in studies lasting to more than a year. The studies demonstrated improved blood sugar control when Januvia was used alone or in patients not satisfactorily managed with metformin or a PPAR agonist.

The most common side effects were upper respiratory tract infection, sore throat, and diarrhea.

Januvia is manufactured by Merck and Co. Inc.

Copyright 2006 by United Press International

Explore further: New US restrictions on painkiller to take effect

add to favorites email to friend print save as pdf

Related Stories

Body by smartphone

Jul 30, 2014

We love our smartphones. Since they marched out of the corporate world and into the hands of consumers about 10 years ago, we've relied more and more on our iPhone and Android devices to organize our schedules, ...

Advancing medicine, layer by layer

Jul 02, 2014

Personalized cancer treatments and better bone implants could grow from techniques demonstrated by graduate students Stephen W. Morton and Nisarg J. Shah, who are both working in chemical engineering professor ...

Recommended for you

New US restrictions on painkiller to take effect

1 hour ago

The federal government is finalizing new restrictions on hundreds of medicines containing hydrocodone, the highly addictive painkiller that has grown into the most widely prescribed drug in the U.S.

Boxed warnings are common in novel therapeutics

Aug 19, 2014

(HealthDay)—Boxed warnings are common on recent drug approvals, and many occur years after approval, according to a research letter published online Aug. 15 in JAMA Internal Medicine.

User comments : 0